Scalper1 News
Biotech Gilead Sciences handily beat first-quarter expectations and raised its revenue guidance Thursday, capping off a busy day for big-cap drugmaker earnings. Gilead (GILD) reported earnings minus one-time items of $2.94 a share, up 99% from the year-earlier quarter and beating analysts’ consensus by 62 cents, according to Thomson Reuters. Revenue jumped 52% to $7.59 billion, more than $600 million above Wall Street’s estimate. Scalper1 News
Scalper1 News